Publication
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort
Journal Paper/Review - Mar 5, 2019
Schmid Sabine, Aeppli Stefanie, Früh Martin
Units
Keywords
lung cancer
Contact
Citation
Schmid S, Aeppli S, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort. Lung Cancer 2019
Type
Journal Paper/Review (English)
Journal
Lung Cancer 2019
Publication Date
Mar 5, 2019
Brief description/objective
Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with antitumor activity in non-small cell lung cancer (NSCLC) with EGFR T790M mutations. The incidence of oligo-progression (PD) on osimertinib is
unknown.